There are growing concerns that Canada’s tax system is holding back productivity and discouraging investment, at a time when ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...
10hon MSNOpinion
John Ivison: Poilievre replays his old, conspiratorial hits as his leadership review nears
National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles ...
Merck’s investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70 billion investment beginning in 2025 to expand domestic manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results